Cimerli (Ranibizumab-Eqrn) Drug Interactions: 5 Moderate
Cimerli (Ranibizumab-Eqrn) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Cimerli. Always confirm against the full prescribing information.
100 interactions
Alendronic acid
The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Alendronic acid.
Level 2 evidence
Ibandronate
The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Ibandronate.
Level 2 evidence
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Ranibizumab.
Level 2 evidence
Aducanumab
The risk or severity of adverse effects can be increased when Ranibizumab is combined with Aducanumab.
Level 2 evidence
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ranibizumab.
Level 2 evidence
Alirocumab
The risk or severity of adverse effects can be increased when Ranibizumab is combined with Alirocumab.
Level 2 evidence
Amivantamab
The risk or severity of adverse effects can be increased when Ranibizumab is combined with Amivantamab.
Level 2 evidence
Anifrolumab
The risk or severity of adverse effects can be increased when Ranibizumab is combined with Anifrolumab.
Level 2 evidence
Ansuvimab
The risk or severity of adverse effects can be increased when Ranibizumab is combined with Ansuvimab.
Level 2 evidence
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Ranibizumab is combined with Anthrax immune globulin human.
Level 2 evidence
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Ranibizumab is combined with Antilymphocyte immunoglobulin (horse).
Level 2 evidence
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ranibizumab.
Cimerli (Ranibizumab-Eqrn) has 168 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Cimerli (Ranibizumab-Eqrn) has 0 major, 5 moderate, and 163 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Cimerli. Always confirm against the full prescribing information.